Henning Lauterbach
Affiliations: | 2005-2007 | Scripps Research Institute, La Jolla, La Jolla, CA, United States |
Google:
"Henning Lauterbach"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Sharma B, Bekerman E, Truong H, et al. (2024) Arenavirus-Based Vectors Generate Robust SIV Immunity in Non-Human Primates. Vaccines. 12 |
| Boopathy AV, Nekkalapudi A, Sung J, et al. (2024) Flt3 agonist enhances immunogenicity of arenavirus vector-based simian immunodeficiency virus vaccine in macaques. Journal of Virology. e0029424 |
| Gomar C, Di Trani CA, Bella A, et al. (2024) Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C. Journal For Immunotherapy of Cancer. 12 |
| Raguz J, Pinto C, Pölzlbauer T, et al. (2024) Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment. Journal For Immunotherapy of Cancer. 12 |
| Purde MT, Cupovic J, Palmowski YA, et al. (2023) A replicating LCMV-based vaccine for the treatment of solid tumors. Molecular Therapy : the Journal of the American Society of Gene Therapy |
| Boopathy AV, Sharma B, Nekkalapudi A, et al. (2023) Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys. Npj Vaccines. 8: 175 |
| Schmidt S, Mengistu M, Daffis S, et al. (2023) Alternating arenavirus vector immunization generates robust polyfunctional genotype cross-reactive HBV-specific CD8 T cell responses and high anti-HBs titers. The Journal of Infectious Diseases |
| Hinterberger M, Endt K, Bathke B, et al. (2023) Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication. Scientific Reports. 13: 5162 |
| Lauterbach H, Schmidt S, Katchar K, et al. (2021) Development and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector Platform. Frontiers in Oncology. 11: 732166 |
| Stutte S, Ruf J, Kugler I, et al. (2021) Type I interferon mediated induction of somatostatin leads to suppression of ghrelin and appetite thereby promoting viral immunity in mice. Brain, Behavior, and Immunity |